Amgen’s Humira biosimilar delayed, Enbrel approved
Amgen’s Humira biosimilar Amjevita will be delayed at least through 2017 due to litigation by competitor AbbVie. The maker of Humira filed a patent infringement claim against Amgen on Aug. 4, alleging that the drug also violates the Biosimilar Price Competition and Innovation Act. Amgen was approved to market its biosimilar Sept. 23 by the Read More →
Sientra loses $10 million in third quarter
Sientra reported a net loss of $10 million for the third quarter of 2016, ended Sept. 30, and announced the acquisition of a new line of products. Sales for the Goleta-based breast implant manufacturer fell from $9.9 million in the third quarter of 2015 to $6.5 million this quarter, while operating expenses rose 15.3 percent. Read More →
Medical marijuana collective raided, CEO arrested
Sespe Creek Collective, one of the tri-county region’s biggest and most visible medical marijuana providers, was raided by Ventura County law enforcement agencies on Nov. 3 and its CEO was arrested on suspicion of multiple felonies. Chelsea Sutula of Ventura, who runs Sespe Creek, spent the night in jail and is now free on bail. Read More →
Sientra settles lawsuits over public offering
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Inogen sales, profits soar in third quarter
Inogen revenues, profits and earnings per share were up for the third quarter, the company announced Nov. 3. Inogen, a Goleta-based manufacturer of direct-to-consumer respiratory products, said revenues increased 33 percent during the quarter from $40.7 million during the same quarter last year to $54.4 million in 2016, which topped analyst revenue estimates of $47.9 Read More →
Wage, break issues spur class action lawsuits
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen beats analysts’ revenue, earnings per share estimates
Amgen revenues increased 2 percent during the third quarter as it beat analysts’ revenue and earnings per share estimates thanks to cost-cutting measures and lower research measures. Revenues for the Thousand Oaks-based biotech giant increased from $5.72 billion during the third quarter of 2015 to $5.81 billion in 2016, which beat analyst estimates of $5.73 Read More →
